Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

Investor Inquiries

Kate Rausch
Investor Relations
617-949-4827
krausch@wavelifesci.com
Information request >

Email Alerts

Sign up here to receive email alerts from Wave Life Sciences.

Press Releases

Press Releases

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a SELECT-HD Clinical Trial of WVE-003 in Huntington’s Disease

Wave Life Sciences to Highlight RNA Editing Capability and AATD and Neurology Programs at 2021 Analyst and Investor Research Webcast on September 28, 2021

Wave Life Sciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Wave Life Sciences to Highlight RNA Editing Modality and PRISM Platform Advancements During Upcoming Scientific Conferences

Wave Life Sciences Reports Second Quarter 2021 Financial Results and Provides Business Update

Wave Life Sciences to Webcast Conference Call of Second Quarter 2021 Financial Results on August 5, 2021

Wave Life Sciences Announces Initiation of Dosing in Phase 1b/2a FOCUS-C9 Clinical Trial of WVE-004 in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia

Wave Life Sciences Announces Proof-of-Concept Preclinical Data for ADAR Editing Program in Alpha-1 Antitrypsin Deficiency

Wave Life Sciences to Present at Jefferies Virtual Healthcare Conference

Wave Life Sciences Reports First Quarter 2021 Financial Results and Provides Business Update